Ozempic (Semaglutide)

If there’s one name most people associate with GLP-1 medications, it’s this one. Ozempic became the face of an entire medication class — showing up in headlines, social media debates, dinner table conversations, and late-night TV monologues. Whether that attention has been helpful or harmful depends on who you ask.

What gets lost in the noise is what Ozempic actually is and what it’s actually approved for. This page cuts through the cultural moment and gives you the full picture — how it works, how it’s dosed, what the clinical trials found, what it costs, and the important distinction between what Ozempic is designed to treat and how it’s often used in practice.

---

The Basics

Ozempic is a brand-name injectable medication made by Novo Nordisk. The active ingredient is semaglutide — the same molecule used in Wegovy (the injection) and Rybelsus (the pill). Same company, same drug, different products for different purposes.

FDA-approved indications:

1. Type 2 diabetes — to improve blood sugar control alongside diet and exercise (approved December 2017)
2. Cardiovascular risk reduction — to reduce the risk of major heart events in adults with Type 2 diabetes and established heart disease (approved 2020)
3. Chronic kidney disease — to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with Type 2 diabetes and CKD (approved January 2025)

That third one is recent and significant — Ozempic became the first and only GLP-1 medication approved for kidney disease protection.[1]

What Ozempic is NOT approved for: weight management. That’s Wegovy. We’ll come back to this distinction — it matters more than you might think.

---

How It’s Delivered

Ozempic comes as a pre-filled, multi-dose pen. Unlike Wegovy (which uses single-dose pens you throw away after each injection), one Ozempic pen contains multiple weekly doses. You dial your dose using a selector on the pen.

The Three Pens

Each pen lasts about a month (one injection per week, four weeks per pen). That’s a practical advantage — one pen per month is simpler to manage than four individual pens.

The Needles

Ozempic pens use NovoFine Plus needles — 32-gauge, 4mm long. To put that in perspective, they’re about as thin as two human hairs. A new needle attaches to the pen for each injection. Extra needles can be purchased separately if needed.[2]

The injection goes under the skin (subcutaneous) in the abdomen, thigh, or upper arm. Same day each week, any time of day, with or without meals.

---

Dosing: How It Works

Ozempic follows a step-up schedule designed to let your body adjust gradually. Starting at the full dose would overwhelm most people’s digestive systems — the nausea would be brutal. The slow ramp-up is intentional and makes a real difference in how tolerable the medication is.

A few things worth knowing:

• The 0.25 mg starting dose isn’t doing much for your blood sugar. Don’t worry if you don’t feel anything dramatic in the first month — that’s expected. It’s laying the groundwork.
• Your provider decides when (and whether) to move you up. Not everyone needs the 2 mg dose. Many people do well at 0.5 mg or 1 mg.
• If a dose increase hits you hard — persistent nausea, can’t keep food down — your provider can extend the current step for a few extra weeks before moving up. Going slower doesn’t reduce the medication’s effectiveness. It just makes the adjustment more manageable.[3]
• Inject on the same day each week. If you miss your usual day, take it within 5 days. If more than 5 days have passed, skip that dose and take the next one on your regular day.

---

What the Research Shows

Ozempic was studied in a series of clinical trials called the SUSTAIN program — a suite of trials testing it against placebo and other diabetes medications. These trials enrolled people with Type 2 diabetes, so the primary goal was blood sugar control. Weight loss was measured as a secondary outcome.

Blood Sugar Control

Across the SUSTAIN trials, Ozempic consistently outperformed the comparisons:

• SUSTAIN 1: 0.5 mg reduced HbA1c by 1.2%, and 1 mg by 1.4%, compared to 0.3% with placebo[4]
• SUSTAIN 2: Superior to sitagliptin (Januvia)
• SUSTAIN 7: Superior to dulaglutide (Trulicity) at both dose levels
• SUSTAIN FORTE: The 2 mg dose showed additional improvement over 1 mg — 59% of patients on 2 mg achieved more than 5% weight loss, compared to 51% on 1 mg[5]

If you’re not sure what HbA1c means: it’s a measure of your average blood sugar over the past 2-3 months. Lower is generally better for people with diabetes, and an HbA1c below 7% is the target for most adults with Type 2 diabetes. Ozempic consistently got more than two-thirds of patients under that threshold.

Weight Loss (in Diabetes Patients)

Because these trials enrolled people with Type 2 diabetes — not people specifically seeking weight loss — the weight results are more modest than what you’ll see in the Wegovy trials. But they’re still meaningful:

For context: Wegovy (semaglutide at 2.4 mg) showed about 15% total body weight loss in its landmark trial — roughly 33 lbs for the average participant. The difference is partly about dose (Ozempic maxes at 2 mg vs. Wegovy at 2.4 mg) and partly about population (people with diabetes tend to lose less weight on GLP-1s than people without diabetes).[6]

The FLOW Trial: Kidney Disease Protection

This is the trial that led to Ozempic’s newest approval — and it’s a big deal.

The FLOW trial enrolled 3,533 patients with Type 2 diabetes AND chronic kidney disease. They were randomized to receive either Ozempic 1 mg weekly or a placebo for an average of about three years.

The headline result: Ozempic reduced the risk of worsening kidney disease, kidney failure, and cardiovascular death by 24%. The absolute risk reduction was about 5% at three years — meaning for every 100 patients treated, about 5 fewer experienced a major kidney event compared to placebo.[7]

The trial also showed an 18% reduction in major cardiovascular events, a 20% reduction in death from any cause, and significantly slowed the rate of kidney function decline.

The evidence was strong enough that an independent safety board actually stopped the trial early — they determined that continuing to give some patients a placebo when the benefit was this clear wasn’t ethical.

---

Side Effects at Ozempic Doses

If you’ve read the “What to Expect” section earlier in this guide, you already know the general picture for GLP-1 side effects. Here’s what the data looks like specifically for Ozempic’s doses.

The Numbers

From pooled clinical trials comparing Ozempic to placebo:[8]

Overall, about a third of people on Ozempic experienced some kind of GI side effect (33-36%), compared to about 15% on placebo. Those numbers are real, but the context matters: severe GI side effects were rare (under 1%), and only about 3-4% of people stopped the medication because of them.

How Ozempic Compares to Wegovy on Side Effects

Because Ozempic’s maximum dose (2 mg) is lower than Wegovy’s maintenance dose (2.4 mg), the side effect profile tends to be milder. The jump from 2 mg to 2.4 mg meaningfully increases GI side effects — overall GI events in Wegovy’s trials reached up to 73%, compared to about 36% with Ozempic. That’s a consideration worth discussing with your provider, especially if you’re someone who’s particularly sensitive to GI symptoms.

---

The Ozempic vs. Wegovy Question

This comes up constantly, so let’s address it directly. Ozempic and Wegovy are the same molecule — semaglutide — made by the same company. Here’s what’s actually different:

Why Doctors Prescribe Ozempic for Weight Loss

This is where it gets practical. Ozempic is frequently prescribed off-label for weight loss — meaning the doctor is prescribing it for something other than its FDA-approved use. This is legal and common in medicine, but it has important implications:

• Insurance: Most insurance plans cover Ozempic for Type 2 diabetes but will NOT cover it when prescribed solely for weight loss. If you have diabetes and weight loss is a secondary goal, Ozempic often makes sense because insurance covers it.
• Supply: During the 2022-2025 shortage period, high off-label demand for weight loss contributed to supply problems for diabetes patients who genuinely needed the medication.
• Dose ceiling: Ozempic’s maximum dose is 2 mg. Wegovy goes to 2.4 mg. That extra 0.4 mg makes a measurable difference in both weight loss results and side effects.

The bottom line: If your primary goal is weight management and you don’t have Type 2 diabetes, Wegovy is the appropriate product to discuss with your provider. If you have Type 2 diabetes and want both blood sugar control and weight loss, Ozempic is a strong option — and often the easier one to get covered.

---

Cost and Access

The cost landscape for GLP-1 medications changes frequently. What follows is accurate as of early 2026, but always verify current pricing with your pharmacy or the manufacturer.

What Ozempic Costs

The NovoCare Savings Card

If you have commercial (private) insurance that covers Ozempic, Novo Nordisk’s savings card can bring your copay down to as little as $25 per month. It provides up to $100 in savings per one-month supply and is valid for up to 48 months from enrollment.[9]

Who qualifies: People with commercial insurance that covers Ozempic. Who doesn’t: Medicare, Medicaid, and other government insurance beneficiaries — they’re not eligible for manufacturer savings cards (this is a federal rule that applies to all pharmaceutical companies, not just Novo Nordisk).

Medicare Coverage

Medicare Part D covers Ozempic for Type 2 diabetes. It does NOT cover Ozempic prescribed off-label for weight loss. For Medicare beneficiaries, the Inflation Reduction Act now caps annual out-of-pocket drug costs, which may help with affordability.

If You Can’t Afford It

Novo Nordisk offers a Patient Assistance Program for eligible uninsured or underinsured patients. Contact NovoCare at 1-866-310-7549 or visit novocare.com to check eligibility.

---

Storage

A practical note: Since each pen contains four weekly doses, a pen lasts about 28 days. The 56-day window gives you plenty of margin — but if you miss doses and the pen sits longer than 56 days from first use, it needs to be discarded regardless of how much medication is left.[10]

---

The Bottom Line

Ozempic is the medication that put GLP-1s on the map — but its name recognition has outpaced the public’s understanding of what it actually does. It’s a diabetes medication first, with additional approvals for heart and kidney protection. The weight loss that made it famous is a real and significant effect, but it’s not what the FDA approved it for.

If you’re taking Ozempic for diabetes, you’re on a medication with a robust evidence base, three distinct FDA approvals, and a dosing system designed to minimize side effects. If you’re considering it for weight loss and don’t have diabetes, it’s worth understanding that Wegovy — the same molecule at a slightly higher dose — is the product specifically designed and approved for that purpose.

Either way, you now have the details that most Ozempic conversations skip over. Use them.

---